<DOC>
	<DOCNO>NCT02327078</DOCNO>
	<brief_summary>This Phase 1/2 , open label study conduct 2 part . The first part study ( Phase 1 ) consist dose-escalation assessment safety tolerability epacadostat administer nivolumab subject select advanced solid tumor lymphomas include melanoma ( MEL ) , non-small cell lung cancer ( NSCLC ) , colorectal cancer ( CRC ) , head neck squamous cell carcinoma ( SCCHN ) , ovarian cancer , B cell non-Hodgkin lymphoma ( NHL ) Hodgkin lymphoma ( HL ) . The second part ( Phase 2 ) study include expansion cohort tumor type test Phase 1 ( except diffuse large B-cell lymphoma ( DLBCL ) lymphoma permit Phase 2 also include cohort glioblastoma ) ) historically good activity nivolumab monotherapy , b ) historically low activity nivolumab monotherapy .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Efficacy Epacadostat Administered Combination With Nivolumab Select Advanced Cancers ( ECHO-204 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject , age 18 year old Subjects histologically cytologically confirm NSCLC , MEL , CRC , SCCHN , ovarian cancer , recurrent B cell NHL HL , glioblastoma Subjects Stage IIIB , Stage IV , recurrent NSCLC ; unresectable Stage IV MEL ; recurrent ( unresectable ) metastatic CRC ; recurrent ( unresectable ) metastatic SCCHN ; FIGO Stage Ic , II , III , IV recurrent ovarian cancer ( unresectable ) relapse refractory B cell NHL ( include relapse refractory DLBCL ) HL , glioblastoma meet follow tumor specific criterion : Subjects Stage IIIB , Stage IV , recurrent NSCLC : Prior systemic therapy must include platinumbased regimen All subject must screen epidermal growth factor receptor ( EGFR ) anaplastic lymphoma kinase ( ALK ) fusion oncogene status positive treat tyrosine kinase inhibitor Malignancy must deem unresectable Subjects unresectable Stage IV MEL : Documentation V600Eactivating BRAF mutation status consent BRAF V600E mutation test screening period Subjects may treatmentnaïve receive 1 prior treatment advance metastatic disease Subjects recurrent ( unresectable ) metastatic CRC : Histologically cytologically confirm adenocarcinoma colon rectum Prior treatment : Progression follow last administration approve standard therapy Subjects recurrent metastatic SCCHN : Metastatic recurrent squamous cell carcinoma amenable local therapy curative intent ( surgery radiation without chemotherapy ) Histologically confirm recurrent metastatic carcinoma nasopharynx salivary gland nonsquamous histology exclude Documentation human papillomavirus status ( eg , p16status ) tumor Subjects International Federation Gynecology Obstetrics ( FIGO ) Stage Ic , Stage II , Stage III , Stage IV , recurrent , persistent ( unresectable ) histologically confirm epithelial ovarian cancer ( EOC ) , primary peritoneal cancer , fallopian tube carcinoma : Subjects must receive platinumtaxanebased regimen frontline therapy Borderline , low malignant potential epithelial carcinoma per histopathology exclude Subjects relapse recurrent B cell NHL HL ( include relapse refractory DLBCL exclude Burkitt 's lymphoma precursor Blymphoblastic leukemia/lymphoma ) : Prior allogeneic stemcell transplantation exclude Not candidate curative therapy hematopoietic stem cell transplantation ( either due disease burden , fitness preference ) Subjects must relapse refractory DLBCL specifically Phase 2 Subjects HL : must brentuximab vedotin refractory intolerant Subjects histologically confirm diagnosis glioblastoma Previous firstline treatment least radiotherapy temozolomide Documented first recurrence glioblastoma diagnostic biopsy contrast enhance magnetic resonance imaging ( MRI ) per RANO criterion MRI within 14 day start study drug An interval least 12 week end prior radiation therapy An interval ≥21 day full recovery surgical resection prior enrollment Presence measurable disease RECIST v1.1 solid tumor Cheson criterion B cell NHL ( include DLBCL ) HL . For subject glioblastoma , presence measurable disease required Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Females childbearing potential male use adequate birth control , screen 125 day last dose study treatment Fresh baseline tumor biopsy ( define biopsy specimen take since completion recent prior chemotherapy regimen ) require cohort except glioblastoma Laboratory medical history parameter within Protocoldefined range unless directly result bone marrow infiltration underlie malignancy Currently pregnancy breastfeed Subjects receive prior immune checkpoint inhibitor ( eg , antiCTLA4 , antiPD1 , antiPDL1 , antibody drug specifically target Tcell costimulation ) IDO inhibitor . Subjects received experimental vaccine immune therapy discuss medical monitor confirm eligibility AntiCTLA4 give firstline treatment metastatic MEL permit Untreated central nervous system ( CNS ) metastases CNS metastasis progress ( eg , evidence new enlarge CNS metastasis new neurological symptom attributable CNS metastasis ) Subjects active inactive autoimmune process Evidence interstitial lung disease active , noninfectious pneumonitis Exclusion specific subject unresectable Stage IV MEL : Ocular MEL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>